Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon γ in renal cell carcinoma cell lines

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 4023-4027

  Ikemoto, Shinichi ^a   Sugimura, Kazunobu ^a   Yoshida, Naomasa ^a   Kuratsukuri, Katsuyuki ^a   Wada, Seiji ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5' Deoxy 5 fluorouridine; 5 Fluorouracil; Interferon ; Renal cell carcinoma; Thymidine phosphorylase

Indexed keywords

DOXIFLURIDINE; FLUOROURACIL; GAMMA INTERFERON;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL DIVISION; DRUG SYNERGISM; FLOXURIDINE; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; PRODRUGS; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED;

EID: 0036875339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Patel NP and Levengood RW: Renal cell carcinoma: natural history and results of treatment. J Urol 119: 722-726, 1977.
2. Swanson DA: Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma? Semin Urol 11: 335-40, 1993
3. Mani S and Poo WJ: Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 19: 149-153, 1996.
4. Kish JA, Neefe JR and Flanigan R: Efficacy of low dose continuous infusion 5-fluorouracil (LDCI-5FU) in recurrent/metastatic (r/m) renal cell carcinoma (RCC). Southwest Oncology Group (SWOG) study. Proc Am Assoc Cancer Res 32: 186, 1991.
5. Romero JA, Alvarez-Vijande R, Gil-Vernet JM Jr, Samson R, Fernandez I, Gutierrez R and Carretero P: Alfa-interferon and oral fluorouracil in the treatment of unremovable and/or metastatic renal cancer. Eur Urol 20: 16-18, 1991.
6. Stella A, Logothetis C, Fritz K, Dexeus F, Amato R and Kilbourri R: Recombinant interferon α (Roferon) combined with 5-fluorouracil-based chemotherapy in metastatic renal cell cancer. J Urol 145: 273A, 1991.
7. Schuth J, Goldschmidt JW and Turin UW: Response in patients with metastatic renal cell carcinoma (RCC) during the treatment with alfa interferon in combination with 5-fluorouracil. Eur J Cancer 29: 234-236, 1993.
8. Murphy BR, Rynard SM, Einhorn LH and Loehrer PJ: A phase II trial of interferon alfa-2a plus fluorouracil in advanced renal cell carcinoma. Invest New Drugs 10: 225-230, 1992.
9. Gebrosky NP, Koukol S, Nseyo UO, Carpenter C and Lamn DL: Treatment of renal cell carcinoma with 5-fluorouracil and alfainterferon. Urology 50: 863-868, 1997.
10. Nishida M, Hino A, Moni K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996.
11. Schwartz EL, Hoffman M, O'Connor CJ and Wadler S: Stimulation of 5-fluorouracil metabolic activation by α interferon in human colon carcinoma cells. Biochem Biophys Res Commun 182: 1232-1239, 1992.
12. Schwartz EL, Baptiste N, Wadler S and Makower D: Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073-19077, 1995.
13. Makower D, Wadler S, Haynes H and Schwartz EL: Interferon induced thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin Cancer Res 3: 923-929, 1997.
14. Elias L and Crissman H: Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48: 4868-4873, 1988.
15. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K and Ishitsuka, H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993.
16. Goto H, Kohno K, Sone S, Akiyama S, Kuwano M and Ono M: Interferon 7-dependent induction of thymidine phosphorylase/platelet-derived endothelial growth factor through γ-activated sequence-like element in human macrophages. Cancer Res 61: 469-473, 2001.
17. Chu E, Zinn S, Boarman D and Allegra CJ: Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50: 5834-5840, 1990.
18. Wilt CL, Smid K, Aherne GW, Noordhuis P and Peters GJ: Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 33: 471-478, 1997.
19. Ishitsuka H, Miwa M, Takernoto K, Fukuoka K, Itoga A and Maruyama H: Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Jpn J Cancer Res 71: 112-123, 1980.
20. Patterson AV, Zhang H, Moghaddam M, Bicknell R, Talbot DC, Stratford IJ and Harris AL: Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675, 1995.
21. Morita T, Matsuzaki A and Tokue A: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 92: 451-456, 2001.
22. Tevaearal HT, Laurent PL, Suardet L, Eliaso JF, Givel JC and Odartchenko N: Interactions of interferon-α2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Eur J Cancer 28: 368-372, 1992.
23. Laurent PL, Tevaearai HT, Eliason JF, Givel JC and Odartchenko N: Interferon alfa and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumors. Eur J Cancer 30: 1859-1865, 1994.
24. Kuriyarna S, Inada T, Shimizu K, Miyakita M and Ogata Y: p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21: 2149-215 3, 2001.
25. Yamamoto Y, Tol M, and Tominaga T: Prediction of the effects of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Res 3: 863-865, 1996.
26. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K and Akiyama S: Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochem Biophys Acta 1034: 107-113, 1990.
27. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H and Tominaga T: Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in human breast cancer. Int J Cancer 64: 79-82, 1995.
28. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata T and Alkou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996.
29. Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S and Ohl Y: Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15: 2570-2578, 1997.